Online inquiry

IVTScrip™ mRNA-Anti-stx1B, Shigamabs®(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ14891MR)

This product GTTS-WQ14891MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets stx1B gene. The antibody can be applied in hemolytic-uremic syndrome (HUS) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Chimeric
RefSeq WP_000752026.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
UniProt ID Q8X4M7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-stx1B, Shigamabs®(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ14891MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11880MR IVTScrip™ mRNA-Anti-GUCY2C, MLN-0264(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA MLN-0264
GTTS-WQ12632MR IVTScrip™ mRNA-Anti-ERBB2, OMNITARG™(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA OMNITARG™
GTTS-WQ2611MR IVTScrip™ mRNA-Anti-ICOSLG, AMG 557(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AMG 557
GTTS-WQ8104MR IVTScrip™ mRNA-Anti-TNFRSF10B, HGS-ETR2(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA HGS-ETR2
GTTS-WQ4837MR IVTScrip™ mRNA-Anti-SDC1, BT-062(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BT-062
GTTS-WQ7013MR IVTScrip™ mRNA-Anti-CSF3R, F-627(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA F-627
GTTS-WQ7879MR IVTScrip™ mRNA-Anti-APCS, GSK-2398852(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GSK-2398852
GTTS-WQ8251MR IVTScrip™ mRNA-Anti-PDCD1, HLX10(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA HLX10
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW